C2N Diagnostics Secures $15M Investment from GHR Foundation for Advanced Alzheimer's Disease Testing
Briefly

from siliconvalleyjournals.com6 months ago
C2N Diagnostics has received a $15 million investment from GHR Foundation to develop non-invasive tests for tau tangles, crucial in Alzheimer's disease diagnosis.
siliconvalleyjournals.comhttps://siliconvalleyjournals.com/c2n-diagnostics-secures-15m-investment-from-ghr-foundation-for-advanced-alzheimers-disease-testing/
Dr. Joel Braunstein emphasized that this new funding will enable C2N to add tau-based blood biomarkers to its portfolio, enhancing diagnostic precision and aiding patient care.
siliconvalleyjournals.comhttps://siliconvalleyjournals.com/c2n-diagnostics-secures-15m-investment-from-ghr-foundation-for-advanced-alzheimers-disease-testing/
The collaboration with GHR Foundation signifies a commitment to improve Alzheimer's disease diagnostics, potentially benefitting patients, families, and healthcare systems impacted by the disease.
siliconvalleyjournals.comhttps://siliconvalleyjournals.com/c2n-diagnostics-secures-15m-investment-from-ghr-foundation-for-advanced-alzheimers-disease-testing/
The investment complements a prior $7.025 million boost from the Alzheimer's Drug Discovery Foundation, furthering efforts in developing mass spectrometry solutions for Alzheimer's testing globally.
siliconvalleyjournals.comhttps://siliconvalleyjournals.com/c2n-diagnostics-secures-15m-investment-from-ghr-foundation-for-advanced-alzheimers-disease-testing/
Read at siliconvalleyjournals.com
#alzheimers-disease #biomarkers #c2n-diagnostics #ghr-foundation #medical-research-funding
[
|
]